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Abstract Of the five PDE4D isoenzymes, only the PDE4D4
cAMP specific phosphodiesterase was able to bind to SH3
domains. Only PDE4D4 and PDE4A5, but not any other
PDE4A, B, C and D isoforms expressed in rat brain, bound to
src, lyn and fyn kinase SH3 domains. Purified PDE4D4 could
bind to purified lyn SH3. PDE4D4 and PDE4A5 both exhibited
selectivity for binding the SH3 domains of certain proteins.
PDE4D4 did not bind to WW domains. We suggest that an
important function of the unique N-terminal region of PDE4D4
may be to allow for association with certain SH3 domain-
containing proteins.
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1. Introduction
The second messenger cyclic AMP (cAMP) exerts control
over a wide range of cellular processes in a cell type speci¢c
fashion [1]. There is an increasing body of evidence to support
the notion that cAMP signalling within cells is functionally
compartmentalised [1,2]. Over the past few years, the machin-
ery which underpins this has been uncovered. This includes
the targeted expression of speci¢c adenylyl cyclase isoen-
zymes, of protein kinase A isoenzymes and of cAMP phos-
phodiesterase (PDE) isoenzymes [1,2].
A large multigene family of enzymes exhibits cAMP PDE
activity, providing the sole route for cAMP degradation in
cells [3^6]. These enzymes are thus poised to exert a profound
in£uence on the intracellular levels of cAMP, as can be dem-
onstrated by the action of inhibitors of these enzymes. Speci¢c
PDE enzyme classes appear to either control or in£uence dis-
tinct functional processes in cells as inhibitors, which are spe-
ci¢c for certain PDE classes and can exert selective e¡ects
[3,7]. This selectivity has been exploited in the development
of various therapeutic agents. Thus, for example, inhibitors
which are selective for the PDE4 enzyme family provide po-
tent anti-in£ammatory agents, exerting selective cellular ef-
fects such as exempli¢ed by the inhibition of TNF-K produc-
tion and action [7].
The PDE4 family of enzymes is encoded by four distinct
genes with additional heterogeneity occurring through alter-
native mRNA splicing [4,6]. This takes the form of 5P domain
swaps, producing proteins with distinct N-terminal regions. A
key role of these N-terminal regions has been suggested [6] to
be in the precise intracellular targeting of certain PDE4 iso-
enzymes. This was initially demonstrated [8] for PDE4A1,
whose unique N-terminal region is responsible for targeting
this protein to a speci¢c intracellular membrane localisation
[9^12]. More recently, other PDE4A isoenzymes [13^15] as
well as various PDE4B [16] and PDE4D [17] isoenzymes
have been shown to exhibit distinct patterns of intracellular
distribution, suggesting that they are too selectively targeted
within cells. In this regard, we have demonstrated [18] that the
rat PDE4A5 isoenzyme as well as its human homologue
PDE4A4 [19] can both interact with the src homology 3
(SH3) domains found in various proteins. SH3 domains are
self-folding structures which allow for protein-protein interac-
tion to occur through their ability to interact with proline-
and arginine-rich regions in the coupled protein target
[20,21]. These domains are utilised by a variety of signalling
proteins, adapter proteins and cytoskeletal proteins.
In this study, we demonstrate that of the ¢ve known iso-
enzymes generated by the PDE4D gene [17], the brain speci¢c
PDE4D4 form can interact with certain SH3 domains ex-
pressed as GST fusion proteins. The screening of a library
of SH3 fusion proteins shows a selectivity for interaction
with those of certain src family tyrosyl kinases. We suggest
that this may indicate a propensity of this isoenzyme to inter-
act with speci¢c SH3 domain-containing proteins.
2. Materials and methods
2.1. Materials
Glutathione-Sepharose was obtained from Pharmacia (St. Albans,
Herts, UK). All tissue culture reagents were from Gibco Life Tech-
nologies (Paisley, UK). [8-3H]Adenosine 3P :5P-cyclic monophosphate
(24 Ci/mmol) and the enhanced chemiluminescence (ECL) detection
system were from Amersham International (Amersham, Bucks, UK).
All other reagents were from Sigma (Poole, Dorset, UK).
2.2. GST fusion proteins
The GST fusion proteins of the SH3 domains of human lck, lyn, src
and fyn were generated by us previously [18] in pGEX-2T. Fusion
proteins of the Csk and Crk SH3 domains were provided by Dr.
Siegmund Fischer (Laboratory of Clinical and Molecular Oncology,
INSERM, Paris, France) and that for c-Abl by Dr. David Baltimore
(Department of Biology, MIT, Cambridge, MA, USA).
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2.3. Puri¢cation of GST fusion proteins
The puri¢cation of GST fusion proteins was performed as described
by us previously in some detail [18].
2.4. Pull down assay for protein-protein interaction
Pull down assays using puri¢ed GST fusion proteins, immobilised
on glutathione-Sepharose resin, were performed on su⁄cient of the
high speed supernatant fraction (100 000Ug) from transiently trans-
fected COS-7 cells to contain 30^40 EU PDE activity as previously
described by us [18].
2.5. Construction of maltose binding protein (MBP) fusion proteins
The full open reading frame of the cDNA encoding the human
PDE4D4 isoform (pPDE39; GenBank accession number L20969;
[17]) was inserted into the NotI site of pMALN [22] to produce
pMALP39. This construct produces a fusion between the MBP and
the amino-terminus of the PDE4D4 protein. The construct was pre-
pared by the addition of NotI sites to the cDNAs by the use of PCR,
as described previously [17]. The construct pMALP39A1 encodes a
fusion between MBP and the amino-terminus of the ¢rst 169 amino
acids of PDE4D4. To generate pMALP39A1, pMALP39 was digested
with the restriction endonucleases BamHI and XbaI. The 5P overhangs
produced by endonuclease digestion were made blunt by ¢lling in with
dNTPs and Klenow fragment and the resulting construct was allowed
to recircularise and was religated with T4 DNA ligase. This procedure
removed the entire insert from pMALP39 except the ¢rst 169 amino
acids, of which the ¢rst 152 are unique to PDE4D4 and the remaining
15 are common to the PDE4D3, PDE4D4 and PDE4D5 isoforms
[17]). It also moved the sequence TAG, originally part of the XbaI
recognition sequence, into the correct reading frame at the end of
codon 169, where it could serve as a stop codon. The structures of
the constructs were veri¢ed by sequencing before use.
2.6. Puri¢cation of MBP fusion proteins
The induction and puri¢cation of MBP fusion proteins was by a
method based on that already described for the puri¢cation of GST
fusion proteins by us [18] but with the following di¡erences. The
Escherichia coli (JM109) cells were transformed with pMAL-c2 (for
the production of MBP) or with pMAL-c2 containing either full
length HSPDE4D4 or the amino-terminal region (residues 1^166) of
HSPDE4D4 as in frame fusion proteins with MBP. The L-broth was
supplemented with glucose (1 mg/ml) as well as with ampicillin
(100 Wg/ml). Expression of the fusion protein was induced by the
addition of IPTG to a ¢nal concentration of 0.3 mM. The culture
was then shifted to 30‡C for the expression of the fusion protein. The
sonicate was cleared by centrifugation at 9000Ug for 30 min and the
supernatant was incubated with amylose resin (New England Biolabs)
equilibrated in phosphate-bu¡ered saline containing 1 mM DTT and
protease inhibitor cocktail. The fusion protein was eluted from the
washed amylose resin by three incubations in 1 ml elution bu¡er
(KHEM supplemented with 10 mM maltose) for at least 10 min
each, end-over-end at 4‡C. The three eluted fractions were pooled
and dialysed at 4‡C against three 600 ml batches of dialysis bu¡er
(50 mM NaCl, 20 mM Tris (pH7 .4)) before being snap frozen as
aliquots. The aliquots were stored at 380‡C until use.
2.7. Overlay assay
Puri¢ed GST fusion proteins were eluted from the glutathione-Se-
pharose beads by three incubations in 100 Wl elution bu¡er (10 mM
glutathione, 50 mM Tris-HCl (pH 8.0)) for at least 10 min each, end-
over-end at 4‡C. The three eluted fractions were pooled and assayed
for their protein concentration, diluted 1:2 with 2ULaemmli bu¡er [2]
and then boiled for 5 min. The boiled samples were loaded onto a
10% sodium dodecyl sulfate (SDS) polyacrylamide gel (10 Wg/lane)
which was run at 40 mA/gel until the dye front reached the bottom.
The samples were then transferred from the gel onto a nitrocellulose
membrane. The membrane was incubated for 1 h at room temperature
with gentle shaking in 100 ml blocking bu¡er (137 mM NaCl, 20 mM
Tris (pH 7.6), 5% skimmed milk powder). The blocked membrane was
washed four times over a 20 min period with T-TBS (137 mM NaCl,
20 mM Tris (pH 7.6), 0.1% Tween-20) and then incubated overnight
at 4‡C with rapid shaking in the presence of 1 Wg of either puri¢ed
MBP or of MBP-HSPDE4D4 diluted in 10 ml dilution bu¡er
(137 mM NaCl, 20 mM Tris (pH 7.6), 1% skimmed milk powder).
The membrane was then washed as before and incubated for 1 h at
room temperature, with rapid shaking, in the presence of an anti-
MBP polyclonal antibody (New England Biolabs) diluted 1:10 000
in dilution bu¡er. The membrane was then washed as before and
incubated for 1 h at room temperature, with rapid shaking, in the
presence of peroxidase-conjugated anti-rabbit IgG (Sigma) diluted
1:20 000 in dilution bu¡er. Finally, the membrane was washed again
as before and the labelled bands were detected according to the Amer-
sham ECL western blotting visualisation protocol.
2.8. Other methods
All other methods used in this study have been described in some
detail previously by us [17,18]. These include the cloning of the
HSPDE4D cDNAs into mammalian expression vectors, the transient
expression of these species in COS-7 cells, the harvesting and fractio-
nation of transfected COS-7 cells, the Western blotting procedure,
reverse transcriptase-PCR procedures and assays for cAMP PDE en-
zyme activity with 1 WM cAMP as substrate.
3. Results
SH3 domains are self-folding structures of around 60 amino
acids whose globular nature and propensity for interaction
with proline- and arginine-rich peptides has been determined
both by NMR and XRD [23,24]. A number of investigators
have screened for putative SH3 domain-interacting proteins
by expressing the SH3 domains of speci¢c proteins as fusion
proteins with GST [20,21,25]. These have been used to capture
interacting proteins in ‘pull down’ assays done upon the bind-
ing of GST to glutathionine agarose. We have utilised this
Fig. 1. Schematic representation of the amino-terminal region of PDE4D4. The top panel shows a representation of the ¢ve known PDE4D
isoenzymes [17]. These are PDE4D1^PDE4D5. The long isoenzymes, PDE4D4 through PDE4D5, contain both the UCR1 and UCR2 regions
which provide unique signatures of the PDE4 enzyme family. The short isoforms, PDE4D1 and 4D2, lack the UCR1 region. The isoenzymes
are characterised by unique N-terminal regions, with the sequence of that of PDE4D4 being shown in the lower panel. Underlined are the three
proline-rich stretches of the sequence.
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procedure [18] to show that the isoenzyme, PDE4A5 (rpde6),
can interact with the SH3 domains of a variety of proteins,
exhibiting a preference for those of src family tyrosyl kinases
lyn and fyn as well as src itself. This interaction was deter-
mined by the unique N-terminal region of PDE4A5 which
contains proline- and arginine-rich motifs.
The PDE4D gene encodes so called ‘long’ and ‘short’ iso-
enzymes (Fig. 1), due to alternative mRNA splicing occurring
at two distinct sites [6,17]. These isoenzymes have unique N-
terminal regions which are encoded by single 5P exons. How-
ever, the long isoenzymes exhibit two domains which are
unique to the PDE4 enzyme family. These are called upstream
conserved region (UCR) 1 and UCR2. In contrast to this, the
short form, PDE4D1, exhibits only the UCR2 region and
PDE4D2 exhibits only the carboxy-terminal portion of
UCR2.
Recently, we have cloned two novel long human PDE4D
isoenzymes [17]. One of these, called PDE4D4, has a unique
136 residue N-terminal region of which 30 residues are pro-
lines and 16 residues are arginines (Fig. 1). The clusters of
proline residues found in this region are indicative of a pro-
pensity for interaction with SH3 domains. Here, we demon-
strate, in a ‘pull down’ assay with the SH3 domain of lyn
tyrosyl kinase, expressed as a GST fusion protein, that human
PDE4A4 can indeed interact with this SH3 domain (Fig. 2A).
In these assays, we mixed recombinant PDE4D4, expressed in
the cytosol of transiently transfected COS-7 cells, with a pu-
ri¢ed lyn SH3-GST fusion protein that was immobilised on
glutathione agarose. This was harvested by centrifugation and
washed before being subjected to SDS-polyacrylamide gel
electrophoresis (PAGE) with subsequent detection of bound
PDE4D4 determined by immunoblotting. This was done with
a monoclonal antibody (mAb) speci¢c for a common C-ter-
minal region found uniquely in PDE4D isoenzymes [17]. Such
analyses identi¢ed the 119 kDa immunoreactive PDE4D spe-
cies that was bound to lyn SH3-GST but did not bind to GST
alone (Fig. 2A). In similar studies, we were able to demon-
strate that neither recombinant PDE4D3 (Fig. 2B) nor
PDE4D5 (data not shown) could bind to the SH3 domains
of src and lyn kinase. These two long PDE4D isoenzymes
only di¡er from PDE4D4 by virtue of their unique N-terminal
regions (Fig. 1). This suggests that PDE4D4 associates with
the SH3 lyn domain through its unique alternatively spliced
N-terminal region. This is consistent with the hypothesis that
the proline-rich sequences (Fig. 1), found in the N-terminal
region of PDE4D4 but not in the N-terminal regions of either
PDE4D3 or PDE4D5, allow PDE4D4 to interact with SH3
domains.
In order to ascertain if endogenously expressed PDE4D4
could bind to SH3 domains, we analysed a soluble extract
from rat brain. We have previously shown [18] that endoge-
nous PDE4A5 found in such an extract can bind to src SH3.
Brain is a good source of a very wide range of PDE4 isoen-
zymes [6] and we have previously shown [17] that species
Fig. 2. Interaction of PDE4D4 with SH3 domains. (A) shows a
PDE4D immunoblot of a ‘pull down’ assay for PDE4D4 with
bound (tracks 3, 5 and 7) and unbound (tracks 2, 4 and 6) frac-
tions. A PDE4D4 standard is shown (track 1) and pull downs with
agarose beads only (tracks 2 and 3), with GST agarose (tracks 4
and 5) and a GST fusion protein of lyn SH3 bound to agarose
(tracks 6 and 7). (B) shows a PDE4D immunoblot of a ‘pull down’
assay for PDE4D3 with bound (tracks 3, 5, 7 and 9) and unbound
(tracks 2, 4, 6 and 8) fractions. A PDE4D3 standard is shown
(track 1) and pull downs with agarose beads only (tracks 2 and 3),
with GST agarose (tracks 4 and 5), with a GST fusion protein of
src SH3 bound to agarose (tracks 6 and 7) and with a GST fusion
protein of lyn SH3 bound to agarose (tracks 6 and 7). (C) shows a
PDE4D immunoblot for standards of PDE4D1+2 (track 1),
PDE4D3 (track 2), PDE4D5 (track 3) and PDE4D4 (track 4), a cy-
tosol extract from rat brain (track 9) and the bound fractions from
pull down assays done on rat brain cytosol with GST fusion pro-
teins of lyn SH3 (track 8), fyn SH3 (track 7) and src SH3 (track 6)
as well as GST alone (track 5). (D) shows an immunoblot of an
overlay assay done using PDE4D4 to probe lanes containing either
GST itself (track 1) or various GST fusion proteins of the SH3 do-
mains of lck (track 2), src (track 3), lyn (track 4), fyn (track 5), crk
(track 6) and csk (track 7). (E) shows a PDE4D immunoblot of a
‘pull down’ assay using puri¢ed MBP fusion protein of PDE4D4
with bound (tracks 3 and 5) and unbound (tracks 2 and 4) frac-
tions. The MBP-PDE4D4 standard is shown (track 1) as are pull
downs with puri¢ed fusion proteins of GST alone (tracks 2 and 3)
and lyn SH3 (tracks 4 and 5). The MBP fusion protein of PDE4D4
had a size of 152 þ 3 kDa. (F) shows a pMal immunoblot of a ‘pull
down’ assay using puri¢ed MBP fusion protein of the N-terminal
region of PDE4D4 with bound (tracks 2 and 3) and unbound
(tracks 1 and 4) fractions. The pull downs were done with puri¢ed
fusion proteins of GST alone (tracks 1 and 2) and GST-lyn SH3
(tracks 3 and 4). The MBP fusion protein of the N-terminal region
of PDE4D4 had a size of 84 þ 2 kDa. These data are typical of ex-
periments done at least three times on separate occasions.
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which co-migrate with recombinant human PDE4D3, D4 and
D5 are expressed there and con¢rm this here (Fig. 2C). Using
the GST fusion proteins of the SH3 domains of src, lyn and
fyn, we show here that these all could bind only rat PDE4D4
(Fig. 2, tracks 6^8). The major PDE4D species in this extract
was PDE4D3, which along with PDE4D5 did not bind to
these SH3 domains. We were also able to con¢rm (data not
shown) previous studies [6,18] that rat brain contains
PDE4B1, PDE4B2, PDE4C2, PDE4A8, PDE4A1 isoenzymes.
However, none of these became associated with the SH3 do-
mains of either src, fyn or lyn (data not shown). This implies
that at least in brain only two PDE4 isoenzymes can interact
with the SH3 domains of these src family tyrosyl kinases,
namely PDE4A5 and PDE4D4.
As an independent method of monitoring potential SH3
domain-PDE4D4 interaction, we also developed an ‘overlay’
assay which also allowed us to demonstrate that the SH3
domains of the src family tyrosyl kinases src, lyn and fyn
could all bind to PDE4D4 (Fig. 2D). The overlay assay was
based upon that used to probe for protein kinase A anchor
proteins [1]. In these experiments, GST and GST fusion pro-
teins of src, lyn and fyn were subjected to SDS-PAGE. Pro-
teins were then transferred to nitrocellulose, the membrane
blocked and then ‘probed’ with a puri¢ed MBP-PDE4D4 fu-
sion protein. The membranes were then washed to remove
unbound MBP-PDE4D4 before being subjected to Western
blotting using either a PDE4 mAb or an anti-MBP Ab so
as to identify bound PDE4D4. The position of binding on
the gel was compared to that where GST and the various
GST fusion proteins were located. This showed that
PDE4D4 did not interact with GST but did bind to the fusion
proteins of src, lyn and fyn SH3 domains (Fig. 2D). These
experiments also showed that PDE4D4 did not bind to the
SH3 domains of lck, crk and csk (Fig. 2D). As a control, we
also performed an overlay probing the blot with MBP alone
(data not shown). This failed to show any interaction with the
various SH3 fusion proteins, ensuring that the detected inter-
actions could not be attributed to the MBP moiety of the
fusion protein.
The overlay assays indicated (Fig. 2D) that PDE4D might
show a preference for interaction with the SH3 domains of
certain proteins. Here (Table 1), we have examined the ability
of PDE4D4 to interact with a panel of di¡erent GST fusion
proteins of SH3 domains. We also investigated an example of
a WW domain [26], namely that found in the Nedd4 protein.
This, like SH3 domains, also interacts with proline-rich pep-
tides but, in contrast to SH3 domains, the target motif usually
includes a tyrosyl residue. Interactions were analysed by pull
down experiments with quantitative assessment given in Table
1 as a ratio of binding relative to that seen for src SH3. This
showed that PDE4D4 bound similarly to the SH3 domains of
the src family tyrosyl kinases lyn, fyn and src as well as to the
SH3 domains of abl tyrosyl kinase and the cytoskeletal pro-
tein fodrin. PDE4D4 also appeared to interact, albeit less
strongly, with the SH3 domains of PI3-kinase and the C-ter-
minal SH3 domain of the adapter protein Grb2. Interestingly,
PDE4D4 did not interact with the N-terminal SH3 domain of
Grb2, which may indicate a di¡erent speci¢city of these two
SH3 domains in Grb2. Neither did PDE4D4 bind to a range
of other SH3 domains, namely those of crk, lck, csk, p53BP2
and cortactin, nor did it bind to the WW domain of Nedd4.
These data imply a distinct speci¢city for the potential inter-
action of PDE4D4 with the SH3 domains of various proteins.
So as to determine if SH3 domain interaction with PDE4D4
was direct, we generated PDE4D4 as a fusion protein with
MBP (PDE4D4-pMAL), expressed it in E. coli and then pu-
ri¢ed it to apparent homogeneity on an amylose resin. Sim-
ilarly, we puri¢ed, to apparent homogeneity, the lyn SH3
domain as a GST fusion protein on glutathionine agarose.
These two proteins were then mixed together and pull down
assays were done using either glutathione agarose (Fig. 2E) or
amylose resin (data not shown), so as to immobilise the one or
other of the partners. These experiments demonstrated that
both species could be pulled down (Fig. 2E). We also gener-
ated a fusion protein of the unique N-terminal 136 residues of
PDE4D4 (NT-PDE4D4-pMAL) with MBP. This fusion pro-
tein was puri¢ed on amylose resin and could be demonstrated
to bind to lyn SH3-GST in a pull down assay (Fig. 2F). These
various experiments are consistent with a direct interaction
between PDE4D4 and a protein SH3 domain.
Using PDE4D4 expressed in the cytosol of transiently
transfected COS-7 cells, we failed, however, to identify any
change in PDE activity (6 5% di¡erence, 1 WM cAMP sub-
strate) when it became bound to lyn SH3. Neither did we see
any change in the dose-dependent ability of Mg2 to activate
PDE4D4 upon binding lyn SH3 (6 5% di¡erence) nor any
di¡erence in the ability of the PDE4 selective inhibitor roli-
pram (4-(3-(cyclopentoxyl)-4-methoxyphenyl)-2-pyrrolidone)
to inhibit PDE4D4 upon binding lyn SH3 (IC50 =
0.10 þ 0.02 = unbound, 0.08 þ 0.02 = bound; means þ S.D.).
4. Discussion
The PDE4D gene encodes ¢ve distinct isoenzymes [17]. Of
these, PDE4D5 has recently been shown [22] to interact with
RACK1 via a small motif within its unique N-terminal region.
Here, we demonstrate that only PDE4D4 can interact with
Table 1
Interaction of PDE4D4 with SH3 domains
Fusion protein PDE4D4 bound PDE4A5 bound
Src SH3 1 (4) 1
Fyn SH3 0.990 þ 0.042 (3) 3.100 þ 0.600
Abl SH3 0.890 þ 0.028 (3) 0.480 þ 0.037
Fodrin SH3 0.882 þ 0.085 (3) nd
Lyn SH3 0.863 þ 0.034 (22) 9.100 þ 0.850
PI3K SH3 0.343 þ 0.114 (3) nd
Grb C SH3 0.289 þ 0.075 (3) nd
Cortactin SH3 0.142 þ 0.076 (3) nd
Csk SH3 0.115 þ 0.022 (5) 0.060 þ 0.020
Lck SH3 0.087 þ 0.015 (3) 0.070 þ 0.016
Grb N SH3 0.068 þ 0.023 (3) nd
Crk SH3 0.058 þ 0.016 (4) 0.050 þ 0.016
P53BP2 SH3 0.033 þ 0.009 (3) 0.516 þ 0.117
Nedd4 WW2 0.055 þ 0.075 (3) nd
GST 0.012 þ 0.007 (26) 0.040 þ 0.050
Analyses were done as described in Section 2 using the ‘pull down’
assay procedure. This utilised GST fusion proteins of the indicated
SH3 and WW domains which were probed against human recombi-
nant PDE4D4 expressed in COS-7 cells. The conditions described in
Section 2 allowed for the association of around 70% of the
PDE4D4 in the assay with the SH3 domain of src kinase. For ready
comparison, data were expressed as binding relative to that to the
SH3 domain of src kinase, set at unity, with means and errors as
S.D. and the indicated number of experiments given in parentheses.
We also give, for comparison, previously published data for
PDE4A5 done under similar conditions [18]. nd = not determined.
FEBS 22773 12-10-99
M.B. Beard et al./FEBS Letters 460 (1999) 173^177176
protein SH3 domains, indicating that such an interaction oc-
curs by virtue of the unique proline-rich N-terminal region
which characterises the PDE4D4 isoenzyme. It appears that
this interaction is direct, as puri¢ed fusion proteins of both
PDE4D4 and its N-terminal region are both capable of bind-
ing to the puri¢ed recombinant lyn SH3 domain.
Whilst the SH3 domains seen in various proteins have a
common three-dimensional globular structure and a propen-
sity for interaction with proline- and arginine-rich peptides in
target proteins, they do show a pronounced speci¢city to-
wards the proteins they select to interact with [23,24]. This
underlies the selective recruitment of proteins to signalling
complexes, such as is seen for the interaction of Grb2 with
SOS. There is, seemingly, a preference for interaction of
PDE4D4 with the SH3 domains of certain proteins (Table
1). From the panel of SH3 domain fusion proteins investi-
gated in this study, we have uncovered a preference for those
of src family tyrosyl kinases lyn, fyn and src itself as well as
the cytoskeletal protein fodrin and abl tyrosyl kinase (Table
1). The PDE4A5 isoenzyme has also been shown to exhibit a
preference for the SH3 domains of src family tyrosyl kinases
[18]. However, PDE4A5 shows ([18] and see Table 1) a dis-
tinct preference within the src family tyrosyl kinase family,
namely for the SH3 domains of lyns s fyns src. It seems
plausible that the selectivities of these two enzymes might
re£ect di¡erences in the form of the proline-rich segments of
their N-terminal regions. Thus that of PDE4A5 is character-
ised by three PxxPxxR motifs [18], whereas polyproline
stretches predominate in PDE4D4 (Fig. 1). This may underlie
the observation we make here that PDE4D4 and PDE4A5
show a di¡erent pattern of interactions for SH3 domain-con-
taining proteins. This, we suggest, is likely to be re£ected by
di¡erences in the range of partners these PDE4 enzymes select
in various cell types and which may thus generate functional
di¡erences in the roles of these two PDE4 species.
The studies described here indicate the propensity of the
PDE4D4 isoenzyme to interact with SH3 domain-containing
proteins. This property is conferred on the enzyme by its
unique N-terminal region. We also show that there is a dis-
tinct speci¢city in the type of SH3 domain that can interact
with PDE4D4. Such analyses provide an initial step in trying
to identify the protein or range of proteins that can interact
with PDE4D4 in the various cell types where it is expressed.
Based on pull down assays done on rat brain, we suggest that
PDE4A5 and PDE4D4 may be either the sole or major PDE4
species able to interact with SH3 domain-containing proteins.
Thus, the potential of these two enzymes to interact with SH3
domain-containing proteins may be related to a major func-
tional role. As with RACK1 binding to PDE4D5 [22], we
were, however, unable to identify any changes occurring in
the catalytic function of PDE4D4 upon its association with
the SH3 domain of lyn. We suggest that the functional im-
portance of any binding of these enzymes to SH3 domain-
containing proteins may be in targeting the PDE4 species to
a speci¢c location within the cell and thus controlling local
cAMP levels.
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